Allergy Program News

Researchers from Children’s Hospital of Philadelphia (CHOP) found that patients with the inflammatory disease eosinophilic esophagitis (EoE) who were treated with the monoclonal antibody dupilumab were able to safely reintroduce foods that would otherwise trigger their symptoms into their diet, with some patients able to reintroduce those foods earlier than others.

The first patient with this specific autoimmunity disorder was identified at CHOP.

A 16-week course could increase the threshold of peanut, tree nuts, egg, milk and wheat that would trigger an allergic reaction.

The Savetts are not a patient family at CHOP, yet they wanted to do something when their daughter, Rachel, died suddenly 23 years ago from anaphylactic shock.

In the largest study of its kind, CHOP researchers have validated a population-level pattern of pediatric allergy development known as the “allergic march.”

A new study involving CHOP researchers found that daily use of a “peanut patch” for one year was effective in desensitizing a majority of peanut-allergic toddlers.

A study involving CHOP researchers found that a weekly dose of dupilumab, a monoclonal antibody, led to a reduction of symptoms and tissue improvement in young adults and adolescents with eosinophilic esophagitis (EoE).

A new study in the Annals of Allergy, Asthma & Immunology shows that a first-of-its-kind program at CHOP can help children with food allergy-related anxiety reduce their fears and improve their quality of life.

Personalized therapeutic approaches for children with eosinophilic esophagitis are gaining ground at CHOP.

Case: A 7-month-old male presented to one of Children’s Hospital of Philadelphia’s After-hours Urgent Care locations with vomiting, dry heaves, and lethargy. It was his third similar episode.